This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Thor, A. Articles by Schlom, J. Search for Related Content PubMed PubMed Citation Articles by Thor, A. Articles by Schlom, J.

Adjunct to the Diagnostic Distinction between Adenocarcinomas of the Ovary and the Colon Utilizing a Monoclonal Antibody (COL-4) with Restricted Carcinoembryonic Antigen Reactivity

Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, Maryland 20892 [A. T., R. M., N. O., M. V., J. S.]; Department of Pathology, Vanderbilt University Hospital, Nashville, Tennessee 37232 [F. G.]; Howard Hughes Medical Institute, Bethesda, Maryland 20892 [M. V.]; and Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710 [C. A. S., W. W. J.]

Malignant ovarian tumors may represent either primary ovarian cancers or metastatic lesions (from patients with demonstrated primary cancers at other body sites) whose distinction may be difficult using clinical, surgical, and pathological criteria. Monoclonal antibody (MAb) COL-4, reactive with carcinoembryonic antigen, has previously been shown to react preferentially with adenocarcinomas of the colon versus a variety of normal tissues. We report here that MAb COL-4 is strongly reactive with primary colonic carcinomas (N = 50), as well as regional (N = 42), and distant (N = 20) metastases of colonic adenocarcinoma. In contrast, MAb COL-4 demonstrated little to no reactivity with primary (N = 53) and metastatic carcinomas of the ovary (N = 23) including serous, mucinous, and poorly differentiated adenocarcinomas using immunohistochemical techniques. This differential reactivity was statistically significant (P < 0.001), suggesting the potential clinical utility of MAb COL-4 in the differentiation of ovarian from colonic adenocarcinoma. Solid-phase quantitative radioimmunoassays and Western blotting techniques confirmed these results. Data are also presented that the carcinoembryonic antigen molecules or epitopes recognized by a more classical broadly reactive anti-carcinoembryonic antigen MAb are distinct from those recognized by MAb COL-4. Other carcinomas which also metastasize to the ovary and may be confused clinically with a primary ovarian tumor such as adenocarcinomas of the stomach and breast were also evaluated for reactivity with MAb COL-4. COL-4 was also reactive with all gastric carcinomas evaluated, but failed to react with breast carcinomas. Hence, COL-4 can now be utilized as an immunohistochemical adjunct for the differentiation of ovarian from gastrointestinal adenocarcinoma which can be difficult to distinguish by clinical, surgical, and histological parameters.

¹ To whom requests for reprints should be addressed, at Laboratory of Tumor Immunology and Biology, National Cancer Institute, NIH, Building 10, Room 8B07, Bethesda, MD 20892.

Received 6/ 9/86. Revised 10/ 3/86. Accepted 10/ 8/86.

This article has been cited by other articles:

				S. C. Chauhan, N. Vinayek, D. M. Maher, M. C. Bell, K. A. Dunham, M. D. Koch, Y. Lio, and M. Jaggi Combined Staining of TAG-72, MUC1, and CA125 Improves Labeling Sensitivity in Ovarian Cancer: Antigens for Multi-targeted Antibody-guided Therapy J. Histochem. Cytochem., August 1, 2007; 55(8): 867 - 875. [Abstract] [Full Text] [PDF]